These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 33542086)

  • 1. Using molecular testing and whole-genome sequencing for tuberculosis diagnosis in a low-burden setting: a cost-effectiveness analysis using transmission-dynamic modelling.
    Mugwagwa T; Abubakar I; White PJ
    Thorax; 2021 Mar; 76(3):281-291. PubMed ID: 33542086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicomponent strategy with decentralised molecular testing for tuberculosis in Uganda: a cost and cost-effectiveness analysis.
    Thompson RR; Nalugwa T; Oyuku D; Tucker A; Nantale M; Nakaweesa A; Musinguzi J; Reza TF; Zimmer AJ; Ferguson O; Turyahabwe S; Joloba M; Cattamanchi A; Katamba A; Dowdy DW; Sohn H
    Lancet Glob Health; 2023 Feb; 11(2):e278-e286. PubMed ID: 36669808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trade-offs between cost and accuracy in active case finding for tuberculosis: A dynamic modelling analysis.
    Cilloni L; Kranzer K; Stagg HR; Arinaminpathy N
    PLoS Med; 2020 Dec; 17(12):e1003456. PubMed ID: 33264288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed diagnosis and treatment of tuberculosis in HIV+ patients in Mozambique: A cost-effectiveness analysis of screening protocols based on four symptom screening, smear microscopy, urine LAM test and Xpert MTB/RIF.
    Orlando S; Triulzi I; Ciccacci F; Palla I; Palombi L; Marazzi MC; Giuliano M; Floridia M; Mancinelli S; Mutemba E; Turchetti G
    PLoS One; 2018; 13(7):e0200523. PubMed ID: 30024890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microscopic observation drug-susceptibility assay vs. Xpert
    Wikman-Jorgensen PE; Llenas-García J; Pérez-Porcuna TM; Hobbins M; Ehmer J; Mussa MA; Ascaso C
    Trop Med Int Health; 2017 Jun; 22(6):734-743. PubMed ID: 28380276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capacity building for whole genome sequencing of Mycobacterium tuberculosis and bioinformatics in high TB burden countries.
    Rivière E; Heupink TH; Ismail N; Dippenaar A; Clarke C; Abebe G; Heusden P; Warren R; Meehan CJ; Van Rie A
    Brief Bioinform; 2021 Jul; 22(4):. PubMed ID: 33009560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The New Xpert MTB/RIF Ultra: Improving Detection of
    Chakravorty S; Simmons AM; Rowneki M; Parmar H; Cao Y; Ryan J; Banada PP; Deshpande S; Shenai S; Gall A; Glass J; Krieswirth B; Schumacher SG; Nabeta P; Tukvadze N; Rodrigues C; Skrahina A; Tagliani E; Cirillo DM; Davidow A; Denkinger CM; Persing D; Kwiatkowski R; Jones M; Alland D
    mBio; 2017 Aug; 8(4):. PubMed ID: 28851844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs.
    Phelan JE; O'Sullivan DM; Machado D; Ramos J; Oppong YEA; Campino S; O'Grady J; McNerney R; Hibberd ML; Viveiros M; Huggett JF; Clark TG
    Genome Med; 2019 Jun; 11(1):41. PubMed ID: 31234910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling the patient and health system impacts of alternative xpert® MTB/RIF algorithms for the diagnosis of pulmonary tuberculosis in Addis Ababa, Ethiopia.
    Tesfaye A; Fiseha D; Assefa D; Klinkenberg E; Balanco S; Langley I
    BMC Infect Dis; 2017 May; 17(1):318. PubMed ID: 28464797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Informing decision-making for universal access to quality tuberculosis diagnosis in India: an economic-epidemiological model.
    Sohn H; Kasaie P; Kendall E; Gomez GB; Vassall A; Pai M; Dowdy D
    BMC Med; 2019 Aug; 17(1):155. PubMed ID: 31382959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India's public sector.
    Lee DJ; Kumarasamy N; Resch SC; Sivaramakrishnan GN; Mayer KH; Tripathy S; Paltiel AD; Freedberg KA; Reddy KP
    PLoS One; 2019; 14(7):e0218890. PubMed ID: 31265470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of microscopic observation drug susceptibility test versus Xpert MTB/Rif test for diagnosis of pulmonary tuberculosis in HIV patients in Uganda.
    Walusimbi S; Kwesiga B; Rodrigues R; Haile M; de Costa A; Bogg L; Katamba A
    BMC Health Serv Res; 2016 Oct; 16(1):563. PubMed ID: 27724908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-benefit analysis of Xpert MTB/RIF for tuberculosis suspects in German hospitals.
    Diel R; Nienhaus A; Hillemann D; Richter E
    Eur Respir J; 2016 Feb; 47(2):575-87. PubMed ID: 26647440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Xpert
    Kohli M; Schiller I; Dendukuri N; Dheda K; Denkinger CM; Schumacher SG; Steingart KR
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012768. PubMed ID: 30148542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The performance of an in-house loop-mediated isothermal amplification for the rapid detection of Mycobacterium tuberculosis in sputum samples in comparison with Xpert MTB/RIF, microscopy and culture.
    Phetsuksiri B; Klayut W; Rudeeaneksin J; Srisungngam S; Bunchoo S; Toonkomdang S; Wongchai T; Nakajima C; Suzuki Y
    Rev Inst Med Trop Sao Paulo; 2020; 62():e36. PubMed ID: 32520211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of the Xpert® MTB/RIF assay for tuberculosis diagnosis in Brazil.
    Pinto M; Steffen RE; Cobelens F; van den Hof S; Entringer A; Trajman A
    Int J Tuberc Lung Dis; 2016 May; 20(5):611-8. PubMed ID: 27084814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: A performance, ease-of-use, and cost evaluation.
    Colman RE; Mace A; Seifert M; Hetzel J; Mshaiel H; Suresh A; Lemmer D; Engelthaler DM; Catanzaro DG; Young AG; Denkinger CM; Rodwell TC
    PLoS Med; 2019 Apr; 16(4):e1002794. PubMed ID: 31039166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Xpert MTB/RIF Ultra performance for pulmonary tuberculosis diagnosis on smear-negative respiratory samples in a French centre.
    Hodille E; Maisson A; Charlet L; Bauduin C; Genestet C; Fredenucci I; Rasigade JP; Lina G; Dumitrescu O
    Eur J Clin Microbiol Infect Dis; 2019 Mar; 38(3):601-605. PubMed ID: 30680567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Xpert MTB/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis: a cost and affordability analysis.
    Pantoja A; Fitzpatrick C; Vassall A; Weyer K; Floyd K
    Eur Respir J; 2013 Sep; 42(3):708-20. PubMed ID: 23258774
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.